Nalpain (Nalbuphine Hydrochloride)

Nalbuphine hydrochloride works by activating kappa opioid receptors, which produce analgesia, while simultaneously blocking mu opioid receptors. This dual action provides pain relief with a lower risk of typical mu‑mediated side effects such as respiratory depression.

The appropriate dose of Nalpain is determined by the prescribing clinician based on the patient’s pain severity, prior opioid exposure, and clinical condition. Dosage may be adjusted for route of administration and individual response.

Safety data for nalbuphine in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To order Nalpain, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Unlike morphine, which is a pure mu‑opioid agonist, Nalpain is a kappa agonist and mu antagonist. This gives it a ceiling effect on respiratory depression and may reduce dependence risk, but it can cause different side‑effect profiles such as dysphoria in some patients.

Nalpain should be stored at ambient temperature, below 25 °C, in its original packaging. Protect it from moisture, direct sunlight and physical damage. Follow standard aseptic techniques when preparing for injection.

Nalpain is supplied as a sterile injectable solution and can be given intramuscularly, intravenously, or subcutaneously. Administration technique follows standard injection protocols, and dosing intervals are set by the treating physician.

The most serious risks include respiratory depression, severe hypotension, and anaphylactic reactions. Patients should be monitored closely for signs of breathing difficulty, sudden drop in blood pressure, or any allergic manifestations during and after administration.

Nalpain is contraindicated in individuals with known hypersensitivity to nalbuphine or any component of the formulation, in patients with severe respiratory depression, acute asthma attacks, or uncontrolled intracranial pressure. Caution is also advised for those with significant hepatic impairment.